Provided by Tiger Trade Technology Pte. Ltd.

Avis Budget

145.55
+7.435.38%
Volume:224.89K
Turnover:31.87M
Market Cap:5.14B
PE:-8.11
High:146.06
Open:137.68
Low:135.13
Close:138.12
52wk High:847.70
52wk Low:85.96
Shares:35.32M
Float Shares:14.85M
Volume Ratio:0.93
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.9408
EPS(LYR):-25.2557
ROE:5800.00%
ROA:2.70%
PB:-1.52
PE(LYR):-5.76

Loading ...

3 AI Stocks Riding Europe’s Credit Growth Trend

Simply Wall St.
·
Aug 28

CAR Group Sets Key Dates for 2026 AGM and Director Nominations

TIPRANKS
·
Aug 28

CAR Group Seeks ASX Quotation for Additional Ordinary Shares

TIPRANKS
·
Aug 28

AI Stocks Riding The Services Boom With Xero SEEK And CAR Group

Simply Wall St.
·
Aug 25

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

GlobeNewswire
·
Aug 24

Xero Stock And 2 AI Software Picks Retail Investors Should Watch

Simply Wall St.
·
Aug 23

PELL Bio-Med's Multi-chain CAR-T Technology Gets Patent in Japan

MT Newswires Live
·
Aug 21

AI Stocks To Watch As Demand Lifts SEEK Xero And CAR Group

Simply Wall St.
·
Aug 21

Is Avis Budget Group (CAR) Fairly Valued On Class Action Lawsuit News?

Simply Wall St.
·
Aug 20

Press Release: CARsgen Therapeutics Announces 2026 Interim Results

Dow Jones
·
Aug 19

Xero Stock And 2 Australian AI Shares Backed By Real World Software Use

Simply Wall St.
·
Aug 18

CARsgen narrows loss and boosts cash on CAR T sales and top-up placing

TIPRANKS
·
Aug 18

3 AI Stocks Riding Real Demand For Cloud And Chip Infrastructure

Simply Wall St.
·
Aug 17

How Investors May Respond To CAR Group (ASX:CAR) FY26 Results And FY27 Growth Guidance

Simply Wall St.
·
Aug 17

AI Stocks To Watch Now As Higher Bond Yields Test Software Leaders

Simply Wall St.
·
Aug 16

AI Stocks To Watch As Chip Demand Lifts Software Growth

Simply Wall St.
·
Aug 15

Avis Budget Group Balances Earnings Strength With Risks

TIPRANKS
·
Aug 15

Beijing's New Policies Drive Cell Therapy Sector with Payment and Approval Reforms, Sparking Industry-wide Value Reassessment

Deep News
·
Aug 14

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

GlobeNewswire
·
Aug 14

Press Release: Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 14